Press Releases

Press Releases

Press Releases

Date Title and Summary Additional Formats
Nov 07, 2019
Genomic Health Stockholders Approve Proposed Acquisition by Exact Sciences
REDWOOD CITY, Calif. , Nov. 7, 2019 /PRNewswire/ --  Genomic Health, Inc.  (NASDAQ: GHDX) announced that its stockholders voted to approve the company's proposed combination with Exact Sciences Corp (NASDAQ: EXAS) at a special meeting held earlier today.
Sep 30, 2019
New TAILORx Data, Published Today in JAMA Oncology, Add to Strong Evidence Base Reinforcing Unique Ability of Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy Treatment
Clinical Outcomes in Patients with High Recurrence Score® Results Presented Today in Oral Session at ESMO 2019 Congress   With Fourth Peer-Reviewed Publication, TAILORx Continues to Elevate Oncotype DX® Test to a New Global Standard     REDWOOD CITY, Calif. , Sept.
Aug 21, 2019
New St. Gallen International Breast Cancer Guidelines Recommend Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy for Node-negative and Node-positive Early-stage Breast Cancer
- Guidelines include TAILORx-defined cutoff of 26 for determining chemotherapy benefit in node-negative disease, and recommend that more women with limited nodal involvement may avoid chemotherapy - Oncotype DX® test recommended based on prospective landmark TAILORx and German PlanB studies,
Jul 29, 2019
Genomic Health Reports 19% Revenue Growth and Record Profit in Second Quarter 2019, Raises Full-Year Guidance
Delivered $114.1M in Revenue and Growth of 19.4% in the Second Quarter Reported $16.0M in Profit and EPS of $0.42 Per Share on a Diluted Basis Raises Full-Year 2019 Revenue and Net Income Guidance Earnings Call and Webcast Previously Scheduled for Thursday, August 1 Will Now Occur Today Monday,
Jul 29, 2019
Exact Sciences and Genomic Health to Combine, Creating Leading Global Cancer Diagnostics Company
Joins two of the strongest brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth Forms best-in-class commercial, research, development and clinical organization, with enhanced scale and scope in cancer diagnostics Global infrastructure
Jul 25, 2019
Genomic Health to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 1, 2019
REDWOOD CITY, Calif. , July 25, 2019 /PRNewswire/ --  Genomic Health, Inc.  (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Thursday, August 1 at 4:30 p.m. Eastern Time to discuss its second quarter 2019 financial results.
Jun 20, 2019
German Federal Joint Committee (G-BA) Issues Exclusive Nationwide Reimbursement Decision for Oncotype DX Breast Recurrence Score® Test
Reimbursement Decision Follows IQWiG's Recommendation Based on TAILORx Study Results REDWOOD CITY, Calif. , June 20, 2019 /PRNewswire/ -- Genomic Health announced today that the German Federal Joint Committee (G-BA) issued a positive reimbursement decision for the Oncotype DX Breast Recurrence
Jun 03, 2019
Secondary Analysis of Landmark TAILORx Results, Published Today in The New England Journal of Medicine, Affirms Unique Ability of Oncotype DX Breast Recurrence Score® to Predict Chemotherapy Benefit, Guiding Adjuvant Therapy with Even Greater Precision
Additional Detail in Patients Age 50 or Younger Presented Today in Oral Session at 2019 American Society of Clinical Oncology ( ASCO ) Annual Meeting TAILORx Continues to Elevate Oncotype DX ® to a New Global Standard with Increasing Utilization and Reimbursement REDWOOD CITY, Calif.
Jun 03, 2019
Updated ASCO Guidelines Establish TAILORx-defined Cutoffs for Determining Chemotherapy Benefit with the Oncotype DX Breast Recurrence Score® Test in Node-negative Breast Cancer
New ASCO Recommendations Increase Proportion of Women Who Can Be Spared Chemotherapy Based on Landmark TAILORx and NSABP B-20 Randomized Clinical Trials Additional Secondary Analysis of TAILORx Trial to be Presented at ASCO Annual Meeting Today REDWOOD CITY, Calif.
May 29, 2019
Genomic Health to Present at the Jefferies 2019 Healthcare Conference
REDWOOD CITY, Calif. , May 29, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that management will present at the Jefferies 2019 Healthcare Conference in New York City on Wednesday, June 5, 2019 at 2 p.m. Eastern Time . To access the live and subsequently archived webcast